U.S. markets open in 3 hours 15 minutes
  • S&P Futures

    +38.00 (+1.16%)
  • Dow Futures

    +320.00 (+1.18%)
  • Nasdaq Futures

    +158.50 (+1.42%)
  • Russell 2000 Futures

    +20.70 (+1.41%)
  • Crude Oil

    -0.30 (-0.75%)
  • Gold

    -10.70 (-0.57%)
  • Silver

    -0.24 (-1.03%)

    +0.0026 (+0.22%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    -1.73 (-6.07%)

    +0.0145 (+1.13%)

    -0.2160 (-0.20%)

    +99.76 (+0.93%)
  • CMC Crypto 200

    +5.81 (+2.67%)
  • FTSE 100

    +76.09 (+1.30%)
  • Nikkei 225

    +307.00 (+1.32%)

Angelman Syndrome Epidemiology Forecast to 2030


‘Angelman Syndrome - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Angelman Syndrome epidemiology in the 7MM, i. e. , the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

New York, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Angelman Syndrome Epidemiology Forecast to 2030" - https://www.reportlinker.com/p05932739/?utm_source=GNW

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030

Angelman Syndrome Understanding

The Angelman Syndrome epidemiology report gives a thorough understanding of the Angelman Syndrome by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Angelman Syndrome in the US, Europe, and Japan. The report covers the detailed information of the Angelman Syndrome epidemiology scenario in seven major countries (US, EU5, and Japan).

Angelman Syndrome Epidemiology Perspective

The Angelman Syndrome epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Angelman Syndrome epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Angelman Syndrome epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Angelman Syndrome Detailed Epidemiology Segmentation

The Angelman Syndrome epidemiology covered in the report provides historical as well as forecasted Angelman Syndrome epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

The Angelman Syndrome report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report
• The Angelman Syndrome report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Angelman Syndrome Epidemiology Report and Model provide an overview of the global trends of Angelman Syndrome in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Angelman Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Angelman Syndrome

• The report provides the segmentation of the Angelman Syndrome epidemiology

Report Highlights

• 11-year Forecast of Angelman Syndrome epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Angelman Syndrome
• Cases of Angelman Syndrome by Mutation Types
• Angelman Syndrome Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Angelman Syndrome?
• What are the key findings pertaining to the Angelman Syndrome epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Angelman Syndrome across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What is the disease risk, burden and unmet needs of Angelman Syndrome?
• What are the currently available treatments of Angelman Syndrome?

Reasons to buy
The Angelman Syndrome Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Angelman Syndrome market
• Quantify patient populations in the global Angelman Syndrome market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Angelman Syndrome therapeutics in each of the markets covered

• Understand the magnitude of Angelman Syndrome population by its epidemiology
• The Angelman Syndrome Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Read the full report: https://www.reportlinker.com/p05932739/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001